<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event - Rivas‐Ruiz, R - 2019 | Cochrane Library</title> <meta content="Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event - Rivas‐Ruiz, R - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009031.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event - Rivas‐Ruiz, R - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009031.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009031.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event" name="citation_title"/> <meta content="Rodolfo Rivas‐Ruiz" name="citation_author"/> <meta content="Insitiuto Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI" name="citation_author_institution"/> <meta content="rivasrodolfo@gmail.com" name="citation_author_email"/> <meta content="Miguel Villasis‐Keever" name="citation_author"/> <meta content="Instituto Mexicano del Seguro Social" name="citation_author_institution"/> <meta content="Guadalupe Miranda‐Novales" name="citation_author"/> <meta content="Centro Medico Nacional Siglo XXI" name="citation_author_institution"/> <meta content="Osvaldo D Castelán‐Martínez" name="citation_author"/> <meta content="Universidad Nacional Autónoma de México" name="citation_author_institution"/> <meta content="Silvia Rivas‐Contreras" name="citation_author"/> <meta content="Instituto de Salud del Estado de Mexico" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD009031.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/03/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009031.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009031.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009031.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Ambulatory Care; Anti-Bacterial Agents [*therapeutic use]; Febrile Neutropenia [chemically induced, *drug therapy, mortality]; Fever [etiology]; *Hospitalization; Length of Stay; Neoplasms [*complications]; Outcome Assessment, Health Care; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Failure" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009031.pub2&amp;doi=10.1002/14651858.CD009031.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009031\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009031\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009031.pub2",title:"Outpatient treatment for people with cancer who develop a low\\u2010risk febrile neutropaenic event",firstPublishedDate:"Mar 19, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009031.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009031.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009031.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009031.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009031.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009031.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009031.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009031.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009031.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009031.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5306 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009031.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/appendices#CD009031-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/table_n/CD009031StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/table_n/CD009031StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#CD009031-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rodolfo Rivas‐Ruiz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#CD009031-cr-0003">Miguel Villasis‐Keever</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#CD009031-cr-0004">Guadalupe Miranda‐Novales</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#CD009031-cr-0005">Osvaldo D Castelán‐Martínez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information#CD009031-cr-0006">Silvia Rivas‐Contreras</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information/en#CD009031-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 March 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009031.pub2">https://doi.org/10.1002/14651858.CD009031.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009031-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009031-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009031-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009031-abs-0001" lang="en"> <section id="CD009031-sec-0001"> <h3 class="title" id="CD009031-sec-0001">Background</h3> <p>People with febrile neutropaenia are usually treated in a hospital setting. Recently, treatment with oral antibiotics has been proven to be as effective as intravenous therapy. However, the efficacy and safety of outpatient treatment have not been fully evaluated. </p> </section> <section id="CD009031-sec-0002"> <h3 class="title" id="CD009031-sec-0002">Objectives</h3> <p>To compare the efficacy (treatment failure and mortality) and safety (adverse events of antimicrobials) of outpatient treatment compared with inpatient treatment in people with cancer who have low‐risk febrile neutropaenia. </p> </section> <section id="CD009031-sec-0003"> <h3 class="title" id="CD009031-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 11) in the Cochrane Library, MEDLINE via Ovid (from 1948 to November week 4, 2018), Embase via Ovid (from 1980 to 2018, week 48) and trial registries (National Cancer Institute, MetaRegister of Controlled Trials, Medical Research Council Clinical Trial Directory). We handsearched all references of included studies and major reviews. </p> </section> <section id="CD009031-sec-0004"> <h3 class="title" id="CD009031-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing outpatient with inpatient treatment for people with cancer who develop febrile neutropaenia. The outpatient group included those who started treatment as an inpatient and completed the antibiotic course at home (sequential) as well as those who started treatment at home. </p> </section> <section id="CD009031-sec-0005"> <h3 class="title" id="CD009031-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial eligibility, methodological quality, and extracted data. Primary outcome measures were: treatment failure and mortality; secondary outcome measures considered were: duration of fever, adverse drug reactions to antimicrobial treatment, duration of neutropaenia, duration of hospitalisation, duration of antimicrobial treatment, and quality of life (QoL). We estimated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data; we calculated weighted mean differences for continuous data. Random‐effects meta‐analyses and sensitivity analyses were conducted. </p> </section> <section id="CD009031-sec-0006"> <h3 class="title" id="CD009031-sec-0006">Main results</h3> <p>We included ten RCTs, six in adults (628 participants) and four in children (366 participants). We found no clear evidence of a difference in treatment failure between the outpatient and inpatient groups, either in adults (RR 1.23, 95% CI 0.82 to 1.85, I<sup>2</sup> 0%; six studies; moderate‐certainty evidence) or children (RR 1.04, 95% CI 0.55 to 1.99, I<sup>2</sup> 0%; four studies; moderate‐certainty evidence). For mortality, we also found no clear evidence of a difference either in studies in adults (RR 1.04, 95% CI 0.29 to 3.71; six studies; 628 participants; moderate‐certainty evidence) or in children (RR 0.63, 95% CI 0.15 to 2.70; three studies; 329 participants; moderate‐certainty evidence). </p> <p>According to the type of intervention (early discharge or exclusively outpatient), meta‐analysis of treatment failure in four RCTs in adults with early discharge (RR 1.48, 95% CI 0.74 to 2.95; P = 0.26, I<sup>2</sup> 0%; 364 participants; moderate‐certainty evidence) was similar to the results of the exclusively outpatient meta‐analysis (RR 1.15, 95% CI 0.62 to 2.13; P = 0.65, I<sup>2</sup> 19%; two studies; 264 participants; moderate‐certainty evidence). </p> <p>Regarding the secondary outcome measures, we found no clear evidence of a difference between outpatient and inpatient groups in duration of fever (adults: mean difference (MD) 0.2, 95% CI ‐0.36 to 0.76, 1 study, 169 participants; low‐certainty evidence) (children: MD ‐0.6, 95% CI ‐0.84 to 0.71, 3 studies, 305 participants; low‐certainty evidence) and in duration of neutropaenia (adults: MD 0.1, 95% CI ‐0.59 to 0.79, 1 study, 169 participants; low‐certainty evidence) (children: MD ‐0.65, 95% CI ‐1.86 to 0.55, 2 studies, 268 participants; moderate‐certainty evidence). With regard to adverse drug reactions, although there was greater frequency in the outpatient group, we found no clear evidence of a difference when compared to the inpatient group, either in adult participants (RR 8.39, 95% CI 0.38 to 187.15; three studies; 375 participants; low‐certainty evidence) or children (RR 1.90, 95% CI 0.61 to 5.98; two studies; 156 participants; low‐certainty evidence). </p> <p>Four studies compared the hospitalisation time and found that the mean number of days of hospital stay was lower in the outpatient treated group by 1.64 days in adults (MD ‐1.64, 95% CI ‐2.22 to ‐1.06; 3 studies, 251 participants; low‐certainty evidence) and by 3.9 days in children (MD ‐3.90, 95% CI ‐5.37 to ‐2.43; 1 study, 119 participants; low‐certainty evidence). In the 3 RCTs of children in which days of antimicrobial treatment were analysed, we found no difference between outpatient and inpatient groups (MD ‐0.07, 95% CI ‐1.26 to 1.12; 305 participants; low‐certainty evidence). </p> <p>We identified two studies that measured QoL: one in adults and one in children. QoL was slightly better in the outpatient group than in the inpatient group in both studies, but there was no consistency in the domains included. </p> </section> <section id="CD009031-sec-0007"> <h3 class="title" id="CD009031-sec-0007">Authors' conclusions</h3> <p>Outpatient treatment for low‐risk febrile neutropaenia in people with cancer probably makes little or no difference to treatment failure and mortality compared with the standard hospital (inpatient) treatment and may reduce time that patients need to be treated in hospital. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009031-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009031-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009031-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009031-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009031-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009031-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009031-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009031-abs-0004" lang="en"> <h3>Outpatient treatment for cancer patient with low‐risk febrile neutropaenic event is effective. </h3> <p><b>Review question</b><br/> Is outpatient treatment with antibiotics safe and effective for people with cancer who have low neutrophil levels (type of white blood cell) and develop a fever (called febrile neutropaenia), usually as a result of chemotherapy? </p> <p><b>Background</b><br/> Neutrophils (a type of white blood cell) are key to fighting bacterial infections. People treated for cancer often have low neutrophil levels, which is called neutropaenia, most commonly because of chemotherapy treatment. This leaves them susceptible to infection, which can become serious and potentially life‐threatening very quickly. This is called neutropaenic sepsis. For many years, people with cancer who develop a fever whilst they are neutropaenic (called neutropaenic fever) have been given antibiotics to prevent them from developing overwhelming neutropaenic sepsis. Depending of the duration of neutropaenia, as well as type of cancer, age and other symptoms, patients can fall in to two risk groups: high‐ or low risk of developing a serious infection. Recently, treatment with oral antibiotics (medicine given as liquid or tablets by mouth) has been proven to be as effective as intravenous (medicine injected into a vein) treatments. However, it is unclear whether providing treatment in an outpatient setting is as safe as therapy administered in a hospital setting. </p> <p><b>Study characteristics</b><br/> Ten studies (994 participants) provided information for the review. These ten studies compared outpatient antibiotic therapy (491 participants) versus inpatient therapy (503 participants) in people with cancer who developed febrile neutropaenia. Six studies were conducted in adults (628 participants) and four studies were in children (366 participants). These ten trials compared effectiveness in terms of the disappearance of signs of infection (mainly fever) and nine studies assessed the effect on mortality (death). Eight studies recorded the number of treatment days for the fever to resolve. Five studies compared the duration of neutropaenia between out‐ and inpatients. Five studies analysed duration of antibiotics usage and six looked at the duration of hospitalisation.Two studies assessed quality of life for patients. </p> <p>In eight of the 10 studies, outpatient antibiotic therapy was part of an early discharge programme, i.e. antibiotics were given for a few days in the hospital and then the participants was discharged home. In the other two studies, the antibiotics were started at home. </p> <p><b>Key results</b><br/> Outpatient antibiotic therapy is probably as effective as inpatient therapy in people (both in adults and children) with cancer who develop febrile neutropaenia for improving the signs of infection, including reducing fever. There was probably little or no difference in mortality between the outpatient therapy and inpatient therapy, as well as in the duration of treatment with antibiotics, or frequency of adverse events related to the use of antibiotics. Treatment as an outpatient may reduce the number of days patients need to be treated in hospital. </p> <p><b>Certainty of the evidence</b><br/> In general, the studies were of moderate certainty. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009031-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-sec-0093">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-sec-0157">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009031-sec-0093"></div> <h3 class="title" id="CD009031-sec-0094">Implications for practice</h3> <section id="CD009031-sec-0094"> <p>Outpatient therapy for the administration of empiric antimicrobial treatment may be an alternative strategy to inpatient therapy for low‐risk cancer patients with an episode of febrile neutropaenia in both adults and children. However, most of the evidence comes of RCTs for early discharge, rather than solely outpatient treatment, and therefore includes the administration of the initial doses of antimicrobials as inpatients and monitoring for twenty‐four hours or more before discharge. </p> </section> <h3 class="title" id="CD009031-sec-0095">Implications for research</h3> <section id="CD009031-sec-0095"> <p>There is a need for RCTs that evaluate outpatient treatment strategies in neutropaenic people with cancer, including low‐income locations, especially in paediatric populations. In a new RCT with the main outcome of treatment failure, based on this meta‐analysis, approximately 622 participants would be necessary in each group to find a difference of 4% between groups. To expand knowledge, RCTs are required where a sole outpatient strategy is evaluated, not just early discharge. </p> <p>In contrast with the adult population, for whom there is a formal classification for risk assessment (MASCC scoring system) (<a href="./references#CD009031-bbs2-0048" title="KlasterskyJ , PaesmansM , RubensteinEB , BoyerM , EltingL , FeldR , et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low‐risk febrile neutropenic cancer patients . Journal of Clinical Oncology2000;18(16):3038‐51. ">Klastersky 2000</a>), for children with cancer and febrile neutropaenia, there is no accepted risk classification. Studies or consensus are required to standardise and offer empirical outpatient therapy in low‐risk children. More RCTs are needed in order to assess the advantages of outpatient treatment, related to different outcomes, including quality of life, cost, and feasibility. </p> <p>To improve the evidence, in future RCTs, the criteria of low risk should be standardised (particularly in children); in addition, a correct random assignment and allocation concealment of the included participants should be ensured. Besides mortality and treatment failure, the outcome variables that need to be evaluated in more depth are duration of fever, adverse effects of antimicrobials, days of hospitalisation, quality of life, patient satisfaction, and costs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009031-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009031-sec-0022"></div> <div class="table" id="CD009031-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Outpatients compared to inpatients ‐ adults for people with cancer who develop a low‐risk febrile neutropaenic event</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Outpatients compared to inpatients ‐ adults for people with cancer who develop a low‐risk febrile neutropaenic event</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Adult patients with cancer who develop a low‐risk febrile neutropaenic event<br/> <b>Setting:</b> Oncology of tertiary care hospitals<br/> <b>Intervention:</b> Outpatient empirical antimicrobial therapy<br/> <b>Comparison:</b> Inpatient empirical antimicrobial therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inpatients ‐ adults</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with outpatients ‐ adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.82 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>628<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000<br/> (92 to 207) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.29 to 3.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>628<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (4 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of fever (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever was 3.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever was</p> <p>on average 0.2 higher<br/> (95% CI 0.36 lower to 0.76 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse drugs reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 8.39<br/> (0.38 to 187.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>375<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (2 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of neutropaenia (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia was 4.7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia was on average 0.1 higher<br/> (95% CI 0.59 lower to 0.79 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalisation (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation ranged from 4.4 to 8.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation was on average ‐1.64 lower<br/> (95% CI ‐2.22 lower to ‐1.06 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Four studies had appropriate allocation processes; in only one study the randomisation process was well stated; none were blinded.<br/> <sup>2</sup> The allocation process was appropriate, but randomisation and blinding were unclear.<br/> <sup>3</sup> CIs were wide.<br/> <sup>4</sup> In two studies, the allocation process was appropriate; in one study, the randomisation process was well stated. Blinding was unclear in three studies.<br/> <sup>5</sup> The allocation process was appropriate in only one study. Randomisation and blinding in the three studies were unclear. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009031-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Outpatients compared to inpatients ‐ children for people with cancer who develop a low‐risk febrile neutropaenic event</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Outpatients compared to inpatients ‐ children for people with cancer who develop a low‐risk febrile neutropaenic event</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Children with cancer who develop a low‐risk febrile neutropaenic event<br/> <b>Setting:</b> Oncology or tertiary care hospitals<br/> <b>Intervention:</b> Outpatient empirical antimicrobial therapy<br/> <b>Comparison:</b> Inpatient empirical antimicrobial therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inpatients ‐ children</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with outpatients ‐ children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.55 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>366<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/> (52 to 187) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/> (0.15 to 2.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>329<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (4 to 66) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of fever (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever ranged from 2.4 to 3.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever was on average ‐0.06 lower<br/> (95% CI ‐0.84 lower to 0.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse drug reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.90<br/> (0.61 to 5.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/> (32 to 315) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of neutropaenia (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia ranged from 3.9 to 12.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia was on average ‐0.65 lower<br/> (95% CI ‐1.86 lower to 0.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalisation (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation was 10.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation was on average ‐3.9 lower<br/> (95% CI ‐5.37 lower to ‐2.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antimicrobial treatment (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of antimicrobial treatment ranged from 4.8 to 10.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of antimicrobial treatment was on average ‐0.07 lower (95%CI ‐1.26 lower to 1.12 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The randomisation process was well stated in two studies; allocation was appropriate in one study; blinding was not done in two studies and was unclear in two studies.<br/> <sup>2</sup> Randomisation was unclear in three studies; the allocation process was well stated in one study; blinding was unclear in two studies and in one was not done.<br/> <sup>3</sup> The randomisation process was well stated in one study; allocation was unclear in three studies; blinding was not done in two studies and in one study was unclear.<br/> <sup>4</sup> CIs were wide.<br/> <sup>5</sup> The randomisation process was well stated in one study; allocation was unclear in two studies; blinding was not done in two studies.<br/> <sup>6</sup> The randomisation and allocation processes were unclear in two studies; blinding was not done in one study and was unclear in one study.<br/> <sup>7</sup> Randomisation and allocation were unclear; blinding was not done.<br/> <sup>8</sup> Statistical tests suggested substantial heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009031-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-sec-0113">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009031-sec-0023"></div> <section id="CD009031-sec-0024"> <h3 class="title" id="CD009031-sec-0024">Description of the condition</h3> <p>Infections are common in people with cancer and neutropaenia (an absolute neutrophil count (ANC) &lt; 500/mm<sup>3</sup> or a count of &lt; 1000 cells/mm<sup>3</sup> with a predicted decrease to &lt; 500 cells/mm<sup>3</sup>). Since these infections are associated with complications, and because fever is often the first and only sign of infection, previous treatment guidelines recommended administration of parenteral (intravenous (IV) or intramuscular (IM)) empirical broad‐spectrum antibiotics, as well as keeping patients in hospital until the clinical signs of infection disappear (<a href="./references#CD009031-bbs2-0022" title="BodeyGP , BuckleyM , SatheYS , FreireichEJ . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine1966;64(2):328‐40. ">Bodey 1966</a>; <a href="./references#CD009031-bbs2-0040" title="HughesWT , ArmstrongD , BodeyGP , BrownA , EdwardsJ , FeldR , et al. Infectious Diseases Society of America. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases1997;25(3):551‐73. ">Hughes 1997</a>; <a href="./references#CD009031-bbs2-0041" title="HughesWT , ArmstrongD ,  BodeyGP ,  BowEJ ,  BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34:730‐51. ">Hughes 2002</a>). </p> <p>Febrile (fever) neutropaenic patients have heterogeneous outcomes; approximately 50% to 60% of patients do not develop life‐threatening complications or fatal infections (<a href="./references#CD009031-bbs2-0023" title="BuchananGR . Approach to treatment of the febrile cancer patient with low‐risk neutropenia. Hematology/Oncology Clinics of North America1993;7(5):919‐35. ">Buchanan 1993</a>; <a href="./references#CD009031-bbs2-0055" title="MullenCA , BuchananGR . Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low‐risk patient. Journal of Clinical Oncology1990;8(12):998‐1004. ">Mullen 1990</a>; <a href="./references#CD009031-bbs2-0058" title="OrudjevE , LangeBJ . Evolving concepts of management of febrile neutropenia in children with cancer. Medical and Pediatric Oncology2002;39(2):77‐85. ">Orudjev 2002</a>), between 48% and 60% have established or occult infections (hidden or not obvious signs of infection), around 20% or more patients with profound neutropaenia (neutrophil counts &lt; 100 cells/mm<sup>3</sup>) have bacteraemia, and a very small percentage of patients (4% to 6%) die as a consequence of a severe bacterial infection (<a href="./references#CD009031-bbs2-0061" title="SantolayaME , AlvarezAM , AvilesCL , BeckerA , CofreJ , EnriquezN , et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clinical Infectious Diseases2002;35(6):678‐83. ">Santolaya 2002</a>; <a href="./references#CD009031-bbs2-0067" title="TalcottJA , FinbergR , MayerRJ , GoldmanL . The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine1988;148(12):2561‐8. ">Talcott 1988</a>; <a href="./references#CD009031-bbs2-0068" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>). Thus, according to the different clinical features and outcomes, febrile neutropaenic episodes might be regarded as low‐ or high‐risk for development of severe infections or serious medical complications. In low‐risk episodes, fever episodes resolve uneventfully. In contrast, patients with high‐risk episodes can have life‐threatening conditions, such as hypotension (low blood pressure), respiratory failure, dehydration or uncontrolled bleeding (<a href="./references#CD009031-bbs2-0061" title="SantolayaME , AlvarezAM , AvilesCL , BeckerA , CofreJ , EnriquezN , et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clinical Infectious Diseases2002;35(6):678‐83. ">Santolaya 2002</a>; <a href="./references#CD009031-bbs2-0067" title="TalcottJA , FinbergR , MayerRJ , GoldmanL . The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine1988;148(12):2561‐8. ">Talcott 1988</a>). </p> <p>Identification of low‐risk patients is useful and leads to a less aggressive empirical antimicrobial therapy. Predictive models were created to discriminate between low‐risk and high‐risk patients (<a href="./references#CD009031-bbs2-0031" title="DelebarreM , MacherE , MazingueF , MartinotA , DubosF . Which decision rules meet methodological standards in children with febrile neutropenia? Results of a systematic review and analysis.. Pediatric Blood &amp; Cancer2014;61(10):1786‐91. ">Delebarre 2014</a>; <a href="./references#CD009031-bbs2-0068" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>). These prognostic scales are based on laboratory and clinical findings during the initial patient assessment in the routine clinical setting (<a href="./references#CD009031-bbs2-0032" title="EltingLS , RubensteinEB , RolstonKV , BodeyGP . Outcome of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clinical Infectious Diseases1997;25(2):247‐59. ">Elting 1997</a>; <a href="./references#CD009031-bbs2-0013" title='KlaassenRJ , GoodmanR , PhamBA , DoyleJJ . "Low‐risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology2000;18(5):1012‐9. '>Klaassen 2000</a>; <a href="./references#CD009031-bbs2-0054" title="MestersRM , HelterbrandJ , UtterbackBG , YanB , ChaoYB , FernándezJA , et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Critical Care Medicine2000;28(7):2209‐16. ">Mesters 2000</a>; <a href="./references#CD009031-bbs2-0061" title="SantolayaME , AlvarezAM , AvilesCL , BeckerA , CofreJ , EnriquezN , et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clinical Infectious Diseases2002;35(6):678‐83. ">Santolaya 2002</a>; <a href="./references#CD009031-bbs2-0065" title="SokerM , ColpanL , EceA , DevecioluC , HaspolatK . Serum levels of IL‐1 beta, sIL‐2R, IL‐6, IL‐8, and TNF‐alpha in febrile children with cancer and neutropenia. Medical Oncology2001;18(1):51‐7. ">Soker 2001</a>; <a href="./references#CD009031-bbs2-0068" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>).The first scale was developed and validated in 1988 by Talcott and colleagues (<a href="./references#CD009031-bbs2-0067" title="TalcottJA , FinbergR , MayerRJ , GoldmanL . The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine1988;148(12):2561‐8. ">Talcott 1988</a>; <a href="./references#CD009031-bbs2-0068" title="TalcottJA , SiegelRD , FinbergR , GoldmanL . Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology1992;10(2):316‐22. ">Talcott 1992</a>). In 2000, an international prospective study established an improved risk assessment model, based on clinical criteria – the Multinational Association for Supportive Care in Cancer (MASCC) index (<a href="./references#CD009031-bbs2-0048" title="KlasterskyJ , PaesmansM , RubensteinEB , BoyerM , EltingL , FeldR , et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low‐risk febrile neutropenic cancer patients . Journal of Clinical Oncology2000;18(16):3038‐51. ">Klastersky 2000</a>). Current guidelines for adult people with cancer recommend using this scale to classify febrile neutropaenia episodes (<a href="./references#CD009031-bbs2-0037" title="HeinzWJ , BuchheidtD , ChristopeitM , VonLilienfeld‐ToalM , CornelyOA , EinseleH , et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology2017;11:1775‐92. ">Heinz 2017</a>; <a href="./references#CD009031-bbs2-0042" title="FreifeldAG , BowEJ , SepkowitzKA , BoeckhMJ , ItoJI , MullenCA , et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update. Clinical Infectious Diseases2011;52(4):427‐31. ">IDSA 2010</a>; <a href="./references#CD009031-bbs2-0051" title="KlasterskyJ , DeNauroisJ , RolstonK , RapoportB , MaschmeyerG , AaproM , et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology2016;25(Suppl 5):v111‐8. ">Klastersky 2016</a>). For paediatric patients, different scales have been proposed (<a href="./references#CD009031-bbs2-0020" title="AlexanderSW , WadeKC , HibberdPL , ParsonsSK . Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. Journal of Pediatric Hematology/Oncology2002;24(1):38‐42. ">Alexander 2002</a>; <a href="./references#CD009031-bbs2-0021" title="AmmannRA , HirtA , LüthyAR , AebiC . Identification of children presenting with fever in chemotherapy‐induced neutropenia at low risk for severe bacterial infection. Medical and Pediatric Oncology2003;41(5):436‐43. ">Ammann 2003</a>; <a href="./references#CD009031-bbs2-0061" title="SantolayaME , AlvarezAM , AvilesCL , BeckerA , CofreJ , EnriquezN , et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clinical Infectious Diseases2002;35(6):678‐83. ">Santolaya 2002</a>) but specific recommendations for their use have not been published (<a href="./references#CD009031-bbs2-0052" title="LehrnbecherT , RobinsonP , FisherB , AlexanderS , AmmannRA , BeaucheminM , et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem‐cell transplantation recipients: 2017 update. Journal of Clinical Oncology2017;35(18):2082‐94. ">Lehrnbecher 2017</a>). </p> <p>Most patients with a febrile neutropaenic episode show no apparent infection source. In approximately 30%, the infection is localised, mainly in the upper respiratory tract or skin, and in 20% to 40% of these infections the episode can be microbiologically documented. It has been observed that the incidence of Gram‐negative organisms has declined and Gram‐positive infections account for 60% to 70% of all microbiologically documented infections in febrile neutropaenic patients (<a href="./references#CD009031-bbs2-0042" title="FreifeldAG , BowEJ , SepkowitzKA , BoeckhMJ , ItoJI , MullenCA , et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update. Clinical Infectious Diseases2011;52(4):427‐31. ">IDSA 2010</a>; <a href="./references#CD009031-bbs2-0044" title="KamanaM , EscalanteC , MullenCA , Frisbee‐HumeS , RolstonK . Bacterial infections in low‐risk febrile neutropenic patients. Cancer2005;104(2):422‐26. ">Kamana 2005</a>). Accordingly, recommendations for empirical antimicrobial therapy have changed during the last decades, but the general principle for the selection of antimicrobial agents still remains. For high‐risk patients, intravenous (IV) administration of broad‐spectrum antibiotics with activity against Gram‐negative and Gram‐positive bacteria is the standard treatment. For low‐risk patients, there are two alternatives, outpatient therapy with oral antibiotics (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>), or hospitalisation with IV broad‐spectrum antibiotics and then switching to oral treatment and discharge (<a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). </p> <p>Antibacterial agents must be selected according to local epidemiology. For low‐risk patients, a variety of schemes have been used, including monotherapy and combinations, by oral or parenteral (intravenous, intramuscular) routes. Some examples are amoxicillin with clavulanate (<a href="./references#CD009031-bbs2-0011" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009</a>; <a href="./references#CD009031-bbs2-0047" title="KlaassenRJ , AllenU , DoyleJ . Randomized placebo‐controlled trial of oral antibiotics in pediatric oncology patients at low risk with fever and neutropenia. Journal of Pediatric Hematology/Oncology2000;22(5):405‐11. ">Klaassen 2000a</a>), ciprofloxacin (<a href="./references#CD009031-bbs2-0036" title="FreifeldA , MarchigianiD , WalshT . A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>), amoxicillin‐clavulanate plus ciprofloxacin (<a href="./references#CD009031-bbs2-0049" title="KlasterskyJ , PaesmansM , GeorgalaA , MuanzaF , PlehiersB , DubreucqL , et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of Clinical Oncology2006;24(25):4129‐34. ">Klastersky 2006</a>) ceftriaxone (<a href="./references#CD009031-bbs2-0011" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009</a>; <a href="./references#CD009031-bbs2-0064" title="SebbanC , DussartS , FuhrmannC , GhesquieresH , RodriguesI , GeoffroisL , et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer2008;16(9):1017‐23. ">Sebban 2008</a>), or aztreonam‐clindamycin (<a href="./references#CD009031-bbs2-0019" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71(11):3640‐6. ">Rubenstein 1993</a>). </p> <p>In 2008, Carstensen and Sorensen published a systematic review of outpatient treatment in febrile neutropaenia (<a href="./references#CD009031-bbs2-0024" title="CarstensenM , SorensenJB . Outpatient management of febrile neutropenia: time to revise the present treatment strategy. Journal of Supportive Oncology2008;6(5):199‐208. ">Carstensen 2008</a>); ten RCTs were included, with six reporting only full outpatient treatment and four comparing outpatient versus inpatient treatment. Of note, mortality and antibiotic‐related side effects were not reported separately according to the intervention (full outpatient, hospital‐based management or early discharge). Since this report, other RCTs have been published (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). A meta‐analysis comparing the effectiveness of empirical antibiotic therapy, either orally or intravenously, was published in 2013 (<a href="./references#CD009031-bbs2-0070" title="VidalL , PaulM , Ben‐DorI , PokroyE , Soares‐WeiserK , LeiboviciL . Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD003992.pub3] ">Vidal 2013</a>). Twenty‐two RCTs were included: in six trials, treatment was given in an outpatients setting; in three trials, authors compared oral treatment between outpatients and inpatients; in two trials, initial therapy was in an inpatient setting and continued in an outpatient setting, and in the rest, all received intra‐hospital treatment. Results demonstrated that oral treatment is as effective as intravenous antibiotic treatment in selected febrile neutropaenic patients, since death and failure rates were similar for both methods, although confidence intervals (CI) were wide: risk ratios (RR) 0.95 (95% CI 0.54 to 1.68) and RR 0.95 (95% CI: 0.85 to 1.07), respectively. </p> </section> <section id="CD009031-sec-0025"> <h3 class="title" id="CD009031-sec-0025">Description of the intervention</h3> <p>Current recommended empiric antimicrobial treatment for low‐risk febrile neutropaenic patients is based on multiple clinical trials and observational studies. There are several alternatives and combinations: one is the election of the route of administration of antimicrobials, and the other is the setting to complete the scheme (outpatient or inpatient). RCTs in the settings are limited in comparing the dose and type of antimicrobials. In some studies, the authors have assessed different types of antibiotics and less aggressive strategies, such as sequential intravenous to oral therapy, or early hospital discharge with continued outpatient therapy. A number of clinical trials have evaluated the effectiveness of inpatient‐administered oral antibiotics (<a href="./references#CD009031-bbs2-0044" title="KamanaM , EscalanteC , MullenCA , Frisbee‐HumeS , RolstonK . Bacterial infections in low‐risk febrile neutropenic patients. Cancer2005;104(2):422‐26. ">Kamana 2005</a>; <a href="./references#CD009031-bbs2-0047" title="KlaassenRJ , AllenU , DoyleJ . Randomized placebo‐controlled trial of oral antibiotics in pediatric oncology patients at low risk with fever and neutropenia. Journal of Pediatric Hematology/Oncology2000;22(5):405‐11. ">Klaassen 2000a</a>). </p> <p>In children, Paganni used ciprofloxacin in low‐risk patients after intravenous broad‐spectrum antibiotics (<a href="./references#CD009031-bbs2-0016" title="PaganiniH , Rodriguez‐BrieshckeT , ZubizarretaP , LatellaA , FirpoV , CasimirL , et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer2001;91(8):1563‐7. ">Paganini 2001</a>). In another study, 126 episodes were evaluated in inpatients where intravenous ceftriaxone showed a success rate of 78%, which was similar (76%) when the same treatment was administered at home (<a href="./references#CD009031-bbs2-0045" title="KarthausM , EgererG , KullmannKH , RitterJ , JürgensH . Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. European Journal of Clinical Microbiology &amp; Infectious Diseases1998;17(7):501‐4. ">Karthaus 1998</a>). Meanwhile, Mustafa and colleagues demonstrated the safety of outpatient ceftriaxone treatment in a pilot study with 19 children; 18 children completed at‐home treatment and only one required hospitalisation as fever persisted for over 48 hours (<a href="./references#CD009031-bbs2-0056" title="MustafaMM , AquinoVM , PappoA , TkaczewskiI , BuchananGR . A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Journal of Pediatrics1996;128(6):847‐9. ">Mustafa 1996</a>). Another clinical trial showed an 89% success rate with ciprofloxacin as ambulatory (outpatient) treatment, after a 24‐hour hospital stay. In this study, participants who needed re‐hospitalisation completed treatment intravenously without complications (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>). Other forms to deliver empirical antimicrobial treatment to low‐risk patients include at‐home administration of short‐term antibiotic schemes (<a href="./references#CD009031-bbs2-0025" title="ChamilosG , BamiasA , EfstathiouE , ZorzouPM , KastritisE , KostisE , et al. Outpatient treatment of low‐risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer2005;103(12):2629‐35. ">Chamilos 2005</a>; <a href="./references#CD009031-bbs2-0026" title="CherifH , BjorkholmM , EngervallP , JohanssonP , LjungmanP , HastR , et al. A prospective, randomized study comparing cefepime and imipenem‐cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scandinavian Journal of Infectious Diseases2004;36(8):593‐600. ">Cherif 2004</a>; <a href="./references#CD009031-bbs2-0027" title="CherifH , JohanssonE , BjorkholmM , KalinM . The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica2006;91(2):215‐22. ">Cherif 2006</a>) or the suspension of antibiotics after the first 24 hours (<a href="./references#CD009031-bbs2-0057" title="NijhuisCO , KampsWA , DaenenSM , GietemaJA , Van derGraafWT , GroenHJ , et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. Journal of Clinical Oncology2005;23(30):7437‐44. ">Nijhuis 2005</a>). </p> </section> <section id="CD009031-sec-0026"> <h3 class="title" id="CD009031-sec-0026">How the intervention might work</h3> <p>In general, the outcome measures used to evaluate the empirical antibiotic therapy in low‐risk patients include defervescence (reduction in fever) after initiating the antibiotics (<a href="./references#CD009031-bbs2-0025" title="ChamilosG , BamiasA , EfstathiouE , ZorzouPM , KastritisE , KostisE , et al. Outpatient treatment of low‐risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer2005;103(12):2629‐35. ">Chamilos 2005</a>), hospital readmission (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>), treatment failure (change of initial empirical antibiotic scheme) (<a href="./references#CD009031-bbs2-0056" title="MustafaMM , AquinoVM , PappoA , TkaczewskiI , BuchananGR . A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Journal of Pediatrics1996;128(6):847‐9. ">Mustafa 1996</a>), death (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0056" title="MustafaMM , AquinoVM , PappoA , TkaczewskiI , BuchananGR . A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Journal of Pediatrics1996;128(6):847‐9. ">Mustafa 1996</a>), adverse events, and costs (<a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>). Also some authors (<a href="./references#CD009031-bbs2-0036" title="FreifeldA , MarchigianiD , WalshT . A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine1999;341(5):305‐11. ">Freifeld 1999</a>; <a href="./references#CD009031-bbs2-0044" title="KamanaM , EscalanteC , MullenCA , Frisbee‐HumeS , RolstonK . Bacterial infections in low‐risk febrile neutropenic patients. Cancer2005;104(2):422‐26. ">Kamana 2005</a>; <a href="./references#CD009031-bbs2-0046" title="KernWV , ComettaA , DeBockR , LangenaekenJ , PaesmansM , GayaH . Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. New England Journal of Medicine1999;341(5):312‐18. ">Kern 1999</a>) have suggested that oral antibiotic therapy may improve quality of life (QoL). </p> <p>Interestingly, although there are some clinical trials that show the effectiveness and safety of outpatient antimicrobial therapy for low‐risk paediatric participants, in a study that explored the feasibility to deliver this type of therapy, 71% of health‐care professionals and 53% of parents would choose ambulatory therapy (<a href="./references#CD009031-bbs2-0066" title="SungL , FeldmanBM , SchwambornG , PaczesnyD , CochraneA , GreenbergML , et al. Inpatient versus outpatient management of low‐risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences. Journal of Clinical Oncology2004;22(19):3922‐9. ">Sung 2004</a>). This could suggest that both patients and health‐care professionals have doubts about the safety of this type of treatment. Quezada and colleagues corroborated these findings in an observational study with children experiencing fever and neutropaenia; in about one‐quarter of episodes, either the family or treating physician did not find the prospect of outpatient care appealing (<a href="./references#CD009031-bbs2-0059" title="QuezadaG , SunderlandT , ChanKW , RolstonK , MullenCA . Medical and non‐medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatric Blood &amp; Cancer2007;48(3):273‐7. ">Quezada 2007</a>). This may be related to the side effects reported (<a href="./references#CD009031-bbs2-0044" title="KamanaM , EscalanteC , MullenCA , Frisbee‐HumeS , RolstonK . Bacterial infections in low‐risk febrile neutropenic patients. Cancer2005;104(2):422‐26. ">Kamana 2005</a>), because some participants treated with at‐home therapy have needed re‐hospitalisation (<a href="./references#CD009031-bbs2-0033" title="EltingLS , LuC , EscalanteCP , GiordanoSH , TrentJC , CooksleyC , et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. Journal of Clinical Oncology2008;26(4):606‐11. ">Elting 2008</a>), or because this approach requires an organised approach and 24 hours, 7 days per week response capacity, educational strategies for families and health‐care professionals, as well as a good doctor‐patient relationship (<a href="./references#CD009031-bbs2-0041" title="HughesWT , ArmstrongD ,  BodeyGP ,  BowEJ ,  BrownAE , CalandraT , et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases2002;34:730‐51. ">Hughes 2002</a>;<a href="./references#CD009031-bbs2-0062" title="SantolayaME . Supportive care in children. Current Opinion in Oncology2010;22(4):323‐9. ">Santolaya 2010</a>). Identification of low‐risk patients as candidates for outpatient management is the first step, but to ensure the effectiveness of this strategy, every issue needs to be addressed (<a href="./references#CD009031-bbs2-0050" title="KlasterskyJ , PaesmansM . The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low‐risk febrile neutropenic cancer patients. Supportive Care in Cancer2013;21(5):1487‐95. ">Klastersky 2013</a>). </p> </section> <section id="CD009031-sec-0027"> <h3 class="title" id="CD009031-sec-0027">Why it is important to do this review</h3> <p>A systematic review was published in 2008 about the effectiveness and safety of outpatient febrile neutropaenia management of low‐risk people with cancer. The authors included only clinical trials in adult participants and concluded that outpatient empirical antimicrobial therapy was safe, effective, and comparable to hospital‐based therapy. However, three of the nine trials did not have a control group (<a href="./references#CD009031-bbs2-0024" title="CarstensenM , SorensenJB . Outpatient management of febrile neutropenia: time to revise the present treatment strategy. Journal of Supportive Oncology2008;6(5):199‐208. ">Carstensen 2008</a>). </p> <p>Considering that outpatient management in recent years has become an alternative for febrile neutropaenia low‐risk patients and the frequency of published studies with this approach has increased, this systematic review aims to analyse the efficacy and safety of outpatient antimicrobial therapy in people with cancer with febrile neutropaenia. If the evidence supports this alternative, this could impact care by decreasing the number of nosocomial (treatment‐related) infections, decrease of exposure to antimicrobials, acquisition of resistant bacteria, decrease of costs and increase of available resources, and improve the quality of life and patient satisfaction. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009031-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-sec-0118">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009031-sec-0028"></div> <p>To compare the efficacy (treatment failure and mortality) and safety (adverse events of antimicrobials) of outpatient treatment compared with inpatient treatment in people with cancer who have low‐risk febrile neutropaenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009031-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-sec-0119">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009031-sec-0029"></div> <section id="CD009031-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009031-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) comparing inpatient empirical antimicrobial therapy with outpatient management for low‐risk febrile neutropaenic people with cancer, using any oral or intravenous antibiotics. </p> </section> <section id="CD009031-sec-0032"> <h4 class="title">Types of participants</h4> <p>Febrile neutropaenic people, both adults or children, with cancer considered as low risk for development of severe infections or serious medical complications. </p> </section> <section id="CD009031-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009031-list-0001"> <li> <p>Outpatient treatment with any oral or intravenous antibiotics, either as monotherapy or combination therapy, administered at home. This group included early hospital discharge after a short course of antibiotics in hospital. </p> </li> <li> <p>Inpatient treatment with any oral or intravenous antibiotics, either as monotherapy or combination therapy, administered during hospitalisation. </p> </li> </ul> </p> </section> <section id="CD009031-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD009031-sec-0035"> <h5 class="title">Primary outcomes:</h5> <p> <ul id="CD009031-list-0002"> <li> <p>Treatment failure: a composite end point comprising one or more of the following: death; persistence, recurrence, or worsening of clinical signs or symptoms of presenting infection; modification of initial empirical antibiotic scheme (<a href="./references#CD009031-bbs2-0029" title="Consensuspanel , Immunocompromised Host Society. The design, analysis,and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Diseases1990;161(3):397‐401. ">Consensus panel 1990</a>; <a href="./references#CD009031-bbs2-0034" title="FeldR . Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?. Supportive Care in Cancer1998;6(5):444‐8. ">Feld 1998</a>; <a href="./references#CD009031-bbs2-0035" title="FeldR , PaesmansM , FreifeldAG , KlasterskyJ , PizzoPA , RolstonKV , et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinical of Infectious Diseases2002;35(12):1463‐8. ">Feld 2002</a>). If studies defined treatment failure differently, the outcome was considered as reported in the study. </p> </li> <li> <p>All‐cause mortality at 30 days follow‐up.</p> </li> </ul> </p> </section> <section id="CD009031-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009031-list-0003"> <li> <p>Duration of fever (days after the start of the intervention).</p> </li> <li> <p>Adverse drug reactions related to the antibiotic regimen, such as nausea, vomiting, diarrhoea. </p> </li> <li> <p>Duration of neutropaenia (days after the start of the intervention).</p> </li> <li> <p>Duration of hospitalisation (hospital stay as reported in the study, including re‐hospitalisations in treatment failure). </p> </li> <li> <p>Duration of antimicrobial treatment (days after the start of the intervention).</p> </li> <li> <p>Quality of life (as reported in the study).</p> </li> </ul> </p> </section> </section> </section> <section id="CD009031-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009031-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 29 November 2018:</p> <p> <ul id="CD009031-list-0004"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 11) in the Cochrane Library (<a href="./appendices#CD009031-sec-0099">Appendix 1</a>); </p> </li> <li> <p>MEDLINE via Ovid (1948 to November week 4, 2018) (<a href="./appendices#CD009031-sec-0100">Appendix 2</a>); </p> </li> <li> <p>Embase via Ovid (1980 to 2018 week 48) (<a href="./appendices#CD009031-sec-0101">Appendix 3</a>); </p> </li> <li> <p>LILACS (1990 to November 2018) (<a href="./appendices#CD009031-sec-0102">Appendix 4</a>). </p> </li> </ul> </p> <p>The search included ongoing trials and unpublished trials in the following trial databases: <a href="https://www.cancer.gov/" target="_blank">National Cancer Institute</a>, <a href="http://www.isrctn.com/page/mrct" target="_blank">MetaRegister of Controlled Trials</a>, <a href="http://www.ctu.mrc.ac.uk/" target="_blank">Medical Research Council Clinical Trial Directory</a>. </p> </section> <section id="CD009031-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We inspected the references of all identified studies as well as major reviews for more studies. We also searched the following conference proceedings for unpublished trials: ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy), ASH (Annual Meeting ‐ American Society of Hematology), IDSA (Infectious Diseases Society of America), ECCMID (European Congress of Clinical Microbiology and Infectious Diseases). </p> </section> </section> <section id="CD009031-sec-0040"> <h3 class="title" id="CD009031-sec-0040">Data collection and analysis</h3> <section id="CD009031-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ODCM and SRC) independently inspected the abstract of each reference identified by the search and applied the inclusion criteria. We obtained all possible relevant abstracts as full‐text articles and two review authors (ODCM and SRC) independently further assessed these for inclusion. </p> <p>We documented the reasons for exclusion and we resolved any disagreements by consensus.</p> </section> <section id="CD009031-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from included trials (OCM, MVK). We resolved any disagreements by consensus or by involving a third person (RRR or MGMN). We documented and discussed the extraction data. We collected all data on an intention‐to‐treat basis, whenever possible. </p> <p>We identified trials by the name of the first author and year in which the trial was first published and ordered chronologically. </p> <p>We extracted, checked, and recorded the following data:</p> <section id="CD009031-sec-0043"> <h5 class="title">1) Characteristics of the trials</h5> <p> <ul id="CD009031-list-0005"> <li> <p>Date, location, and setting trial (e.g. inpatients or ambulatory patients (outpatients))</p> </li> <li> <p>Case definitions used (inclusion and exclusion criteria)</p> </li> <li> <p>Country</p> </li> <li> <p>Sponsor of trial (specified, known or unknown)</p> </li> <li> <p>Design (intention‐to‐treat, method of randomisation, and allocation)</p> </li> </ul> </p> </section> <section id="CD009031-sec-0044"> <h5 class="title">2) Characteristics of participants</h5> <p> <ul id="CD009031-list-0006"> <li> <p>Number of participants in each group</p> </li> <li> <p>Age (median, mean)</p> </li> <li> <p>Type of participant (child, adult)</p> </li> <li> <p>Gender</p> </li> <li> <p>Underlying malignancy (haematological or solid)</p> </li> <li> <p>Neutrophil count in each group (below 1,000 or 500 or 100/mm<sup>3</sup>) </p> </li> </ul> </p> </section> <section id="CD009031-sec-0045"> <h5 class="title">3) Characteristics of interventions</h5> <p> <ul id="CD009031-list-0007"> <li> <p>Type of intervention: exclusively as inpatient; exclusively as outpatient; early discharge (e.g. 24 hours to 48 hours as inpatient, then as outpatient) </p> </li> <li> <p>Initially with intravenous (IV) therapy followed by oral therapy</p> </li> </ul> </p> </section> <section id="CD009031-sec-0046"> <h5 class="title">4) Characteristics of outcome measures</h5> <p> <ul id="CD009031-list-0008"> <li> <p>Treatment failure</p> </li> <li> <p>Mortality</p> </li> <li> <p>Duration of fever</p> </li> <li> <p>Adverse drug reactions related to the antibiotics</p> </li> <li> <p>Duration of neutropaenia</p> </li> <li> <p>Duration of hospitalisation</p> </li> <li> <p>Duration of antimicrobial treatment</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> </section> </section> <section id="CD009031-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RRR, OCM) assessed the methodological quality of included RCTs in accordance with guidelines in the Cochrane Handbook (<a href="./references#CD009031-bbs2-0039" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org/. ">Higgins 2011</a>). Each quality component was classified according to 'Risk of bias' assessment tool as low, high, or unclear risk of bias. </p> <section id="CD009031-sec-0048"> <h5 class="title">Sequence generation</h5> <p>The method of randomisation was noted on the data extraction form. We coded the randomisation of participants to intervention groups as: low risk of bias (e.g. a computer‐generated random sequence or a table of random numbers), high risk of bias (e.g. date of birth, clinic ID, number, or surname), unclear (insufficient information). </p> </section> <section id="CD009031-sec-0049"> <h5 class="title">Allocation concealment</h5> <p>We coded the concealment of allocation sequence as low risk of bias (e.g. central allocation, sealed envelopes), high risk of bias (e.g. open random allocation, envelopes unsealed), unclear (e.g. not reported, insufficient information). </p> </section> <section id="CD009031-sec-0050"> <h5 class="title">Blinding of participants, personnel, outcome assessors</h5> <p>Low risk of bias (e.g. blinding of personnel or participants, or non‐blinding but appropriately assessed), high risk of bias (e.g. incomplete blinding or no blinding when outcome measure would be likely to be biased), unclear (e.g. insufficient data). </p> </section> <section id="CD009031-sec-0051"> <h5 class="title">Incomplete outcome data</h5> <p>Low risk of bias (e.g. no missing data, missing data balanced between groups), high risk of bias (e.g. missing data of one or more of the primary outcome measures), unclear (insufficient information). </p> </section> <section id="CD009031-sec-0052"> <h5 class="title">Selective reporting</h5> <p>Low risk of bias (e.g. all expected outcomes were reported), high risk of bias (e.g. not all of the primary outcomes were reported), unclear (insufficient information). </p> </section> </section> <section id="CD009031-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>From each individual trial, for dichotomous variables (treatment failure, mortality, adverse drug reactions), the proportion was calculated by dividing the number of events in each group with the total population in the group. For continuous variables (duration of fever, duration of neutropaenia, duration of antimicrobial treatment, and duration of hospitalisation), we extracted means and standard deviations (SDs) reported from each group. If the median was reported, and the 95% confidence interval (CI) was available, then the SD was calculated. In studies where only median and range was reported, the data were extracted as reported. </p> </section> <section id="CD009031-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>The statistical unit of the analysis was the individual participant.</p> </section> <section id="CD009031-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>Some studies did not report the standard deviation, which was calculated from the median and CIs. </p> </section> <section id="CD009031-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>For the interpretation of heterogeneity, the number of participants in each RCT, magnitude and direction of the effect, as well as the CIs were taken into account. For example, in the children's studies, the outcome variable (treatment failure) results of the intervention pointed in both directions. We assessed the level of heterogeneity (degree of difference between the results of different trials) between the results of the trials initially by inspection of the graphical presentations and by calculating a test of heterogeneity (Chi‐squared, I<sup>2</sup>) (<a href="./references#CD009031-bbs2-0030" title="DeeksJJ , AltmanDJ , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care; Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001. ">Deeks 2001</a>; <a href="./references#CD009031-bbs2-0038" title="HigginsJP , ThomsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>). We considered substantial heterogeneity levels if I<sup>2</sup> was more than 50%. </p> </section> <section id="CD009031-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>Due to the paucity of studies in each analysis, a funnel plot could not be analysed.</p> </section> <section id="CD009031-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We pooled the results from clinically similar studies in meta‐analyses using <a href="./references#CD009031-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> (RevMan 5). </p> <p> <ul id="CD009031-list-0009"> <li> <p>For any dichotomous outcomes, we pooled RRs, with 95% CIs;</p> </li> <li> <p>For continuous outcomes, we pooled the weighted mean differences (MD) with 95% CIs between the treatment arms. </p> </li> </ul> </p> <p>All meta‐analyses were performed using a random‐effects model (Mantel‐Haenszel method).</p> <section id="CD009031-sec-0059"> <h5 class="title">Summary of findings and certainty of evidence</h5> <p>Two review authors (RRR, OCM) independently rated the quality for each outcome. We provided a source and rationale for each assumed risk cited in the table(s) and we used the GRADE system to rank the certainty of the evidence using the GRADEprofiler Guideline Development Tool (<a href="http://gradepro.org/" target="_blank">GRADEproGDP</a>) and the guidelines provided in Chapter 12.2 of the Cochrane Handbook (<a href="./references#CD009031-bbs2-0063" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). We presented a summary of the evidence in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences for each relevant comparison of alternative management strategies, the number of participants and studies addressing each important outcome, and the rating of the overall confidence in the effect estimates for the comparisons of each major primary outcome, including potential harms, as outlined in the <a href="#CD009031-sec-0034">Types of outcome measures</a> section: </p> <p> <ul id="CD009031-list-0010"> <li> <p>Treatment failure;</p> </li> <li> <p>Mortality;</p> </li> <li> <p>Duration of fever;</p> </li> <li> <p>Adverse drug reactions related to the antibiotic regimen;</p> </li> <li> <p>Duration of neutropaenia;</p> </li> <li> <p>Duration of hospitalisation;</p> </li> <li> <p>Duration of antimicrobial treatment.</p> </li> </ul> </p> <p>We downgraded the evidence from 'high' certainty by one level for serious (or by two for very serious) concerns for each limitation: </p> <p> <ul id="CD009031-list-0011"> <li> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> <section id="CD009031-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Considering that adult cancer patients are different from paediatric patients, all the data were presented separated for each group. </p> <p>We performed subgroup analyses to investigate the effects of the type of intervention (exclusively inpatient versus exclusively outpatient; inpatient versus early discharge). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009031-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009031-sec-0061"></div> <section id="CD009031-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD009031-sec-0063"> <h4 class="title">Results of the search</h4> <p>See PRISMA flow diagram <a href="#CD009031-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009031-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009031-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The search strategy identified 1839 publications, after title and abstract screening. We considered 19 as potentially relevant publications and obtained the full‐text versions for further evaluation. We included a total of ten randomised controlled trials (RCTs) which fulfilled all the inclusion criteria (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). We reported details of each in the <a href="./references#CD009031-sec-0111" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD009031-sec-0064"> <h4 class="title">Included studies</h4> <p>The ten RCTs we identified had been published between 1995 and 2014 and included a total of 994 participants (range: 45 to 169 participants per trial). Half of the trials were single‐centre studies (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>), and the other half were multicentre studies (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). </p> <p>The single‐centre studies were performed in Spain (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>), UK (<a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>), Egypt (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>), Mexico (<a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>) and Australia (<a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>). In the case of multicenter studies, three (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>) were carried out in hospitals in one country (Egypt, Chile, and USA, respectively); one study was carried out in hospitals in Switzerland and Germany (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>) and one (<a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>) in six countries (South Africa, Colombia, Israel, Perú, Argentina, Spain). </p> <section id="CD009031-sec-0065"> <h5 class="title">Type of participants</h5> <p>Of the total participants, 52.3% were women, with a male to female ratio of 0.91. In five studies, the ages of participants ranged from 18 to 81 years (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). Four studies included paediatric participants only (under 18 years) (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>) and in the remaining study (<a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>), the age of participants ranged from 10 to 63 years (this study was included in the analysis for adults). </p> <p>With regard to the type of cancer, five studies included participants diagnosed with leukaemia, lymphoma, and solid tumours (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>); in three studies, participants had solid tumours and lymphomas (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>); in one study, participants had acute lymphoblastic leukaemia and solid tumours (<a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>), and in another participants had only acute lymphoblastic leukaemia (<a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>). Thus, it should be noted that in all of the 10 studies, participants with leukaemia and lymphoma were included, ranging from 4.7% to 100% (median 39%). </p> </section> <section id="CD009031-sec-0066"> <h5 class="title">Low‐risk febrile neutropaenic definitions</h5> <p>In additional <a href="#CD009031-tbl-0003">Table 1</a>, we describe the criteria used to consider low‐risk febrile episodes in the included studies. The definitions were not standardised, but criteria were consistent with regard to the following aspects: participants must not have comorbidities requiring hospitalisation, focal and/or severe infections, or relapse of the disease, and must not be receiving intensive chemotherapy. </p> <div class="table" id="CD009031-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria used to consider low‐risk febrile episodes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk definition used</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants that did not have any of the following: history of recurrent pyrexia or undetermined origin; shock (systolic blood pressure &lt; 80 mmHg or peripheral circulatory failure); any comorbid condition requiring hospitalisation (except anaemia or thrombocytopaenia); and expectation of prolonged neutropaenia (&gt; 7 days) based on aplastic anaemia, myelodysplasia, leukaemia or other causes, except if leukaemia patients were receiving consolidation of maintenance therapy or growth stimulation factors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients that did not have renal failure requiring dialysis, suspected meningitis, known HIV infection, septic shock, or likelihood to expire within 48 h of study entry. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and did not have any of the following: progression of their malignant disease; signs or symptoms of a potentially severe infection (hypotension, oliguria, altered mental status, tachypnoea, respiratory failure, clotting abnormality, or acidosis); a serious focal infection (pneumonia, extensive cellulitis, meningitis, or pyelonephritis); hypercalcaemia; uncontrolled bleeding; cardiac, renal or liver failure; or another comorbid condition that required admission to the hospital. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were required to be haemodynamically stable with no signs or symptoms that required intravenous fluid support, and adequate renal function. </p> <p>Participants must not have a coexisting medical condition that would require targeted or prolonged duration of antibiotic therapy (e.g. cellulitis, abscess, pneumonia, CVC tunnel infection). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with acute leukaemia in complete remission, absence of an identifiable focus of infection (except for acute respiratory infections); absence of comorbidity conditions or organ failure (except for bone marrow); expected recovery of neutropaenia (&gt; 0.10 x 10<sup>9</sup>/L) in the next 8 days. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were evaluated for risk assessment criteria by the author. Participants did not have an indication for hospitalisation (other than fever); systemic hypotension; altered mental status; respiratory failure or inadequate oral fluid intake during 24 h observation; AIDS‐associated malignancy; neutropaenia arising from more than 21 days of chemotherapy and intensive chemotherapy requiring bone marrow or peripheral stem‐cell support. </p> <p>For leukaemia, participants must have bone marrow‐proven complete remission, and without leukaemia, no evidence of disease progression after the initial chemotherapy regimen or at least two cycles of a subsequent regimen. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were evaluated with a previously validated risk prediction model. Participants with less than 90 mg/L serum‐C reactive protein (CRP), absence of hypotension, absence of relapse or leukaemia as cancer type, platelet count of &gt; 50,000/μL and &gt; 7 days of receiving chemotherapy were classified as low risk. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The following criteria must be fulfilled at 72 h: afebrile for a minimum of 24 h prior to the assessment point; negative initial blood cultures or two negative repeat blood cultures (24 h apart) if initially positive; absence (or substantial resolution) of manifestations of localised infection; Lansky performance scale 80 to 100, Karnosfy scale 80 to 100 if &gt; 16 years; neutrophil absolute count &gt; 100 μL; patient not in or after first induction therapy for acute myeloblastic leukaemia; discharge destination 1 h travel time from the medical centre. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants had to fulfil 10 predefined low‐risk criteria: diagnosis not AML/mature B‐ALL/NHL; bone marrow involvement &lt; 25%; no comorbidity requiring hospitalisation: no arterial hypotension, no hypo‐oxygenation [SpO<sub>2</sub> &lt; 94% at ambient air], no radiologically defined pneumonia, no focal infection, initial blood cultures negative and fever always &lt; 39.5°C. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients were considered low risk if they had: no signs of septic shock (including hypotension, tachycardia, delayed capillary refill or rigor); no significant comorbidities requiring inpatient monitoring or treatment including clinical focus of infection, pain, mucositis, vomiting, diarrhoea, or dehydration; no acute myeloid leukaemia diagnosis (AML), mature B‐cell lymphoma diagnosis, or were not in the induction phase of acute lymphoblastic leukaemia, or were not receiving predominantly high dose stem cell‐supported chemotherapy. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AIDS: acquired immune deficiency syndrome<br/> AML: acute myeloid leukaemia<br/> B‐ALL: Cell B‐ acute lymphoblastic leukaemia<br/> CRP: serum‐C reactive protein<br/> CVC: central venous catheter<br/> ECOG: Eastern Cooperative Oncology Group<br/> NHL: non‐Hodgkin lymphoma </p> </div> </div> </section> <section id="CD009031-sec-0067"> <h5 class="title">Intervention</h5> <p>It is important to mention that in most of the RCTs (N = 8) the intervention was early discharge: participants were kept under surveillance for 24 to 72 hours in hospital before returning home (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). In only two studies, participants were discharged almost immediately after randomisation (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>), so, these two trials compared empiric antimicrobial therapy in exclusively outpatient versus exclusively inpatient settings. In these two studies, the proportion of participants with solid tumours were 69.2% and 89.5%. </p> <p>As for the type of empirical antimicrobial therapy used, hospitalised participants were given intravenous treatment in nine studies and in only one study participants received oral ofloxacin (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>). In contrast, participants who were discharged to their home received the antimicrobial treatment orally in six studies (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>) and, in four studies (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>), treatment was administered parenterally by nurses. </p> <p>Empirical antimicrobial schemes used differed among studies. In hospitalised participants, the combination of two antimicrobials was used in most studies, whereas three studies used monotherapy: ofloxacin (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>), imipenem (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>) or cefepime (<a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>). In the five outpatient studies, ofloxacin (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>), cefuroxime (<a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>), gatifloxacin (<a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>), or cefepime (<a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>) was administered as monotherapy. </p> </section> </section> <section id="CD009031-sec-0068"> <h4 class="title">Excluded studies</h4> <p>We excluded nine studies for reasons described in the <a href="./references#CD009031-sec-0112" title="">Characteristics of excluded studies</a> table. Reasons for exclusion were the following: </p> <p> <ul id="CD009031-list-0012"> <li> <p>Studies which randomised oral versus intravenous antibiotic treatment in outpatients: seven trials (<a href="./references#CD009031-bbs2-0011" title="GuptaA , SwaroopC , AgarwalaS , PandeyRM , BakhshiS . Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology2009;31(9):635‐41. ">Gupta 2009</a>; <a href="./references#CD009031-bbs2-0014" title="MinottiV , GentileG , BucaneveG , IoriAP , MicozziA , CavicchiF , et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Supportive Care in Cancer1999;7(3):134‐9. ">Minotti 1999</a>; <a href="./references#CD009031-bbs2-0015" title="MullenCA , PetropoulosD , RobertsWM , RyttingM , ZipfT , ChanKW , et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer1999;86(1):126‐34. ">Mullen 1999</a>; <a href="./references#CD009031-bbs2-0016" title="PaganiniH , Rodriguez‐BrieshckeT , ZubizarretaP , LatellaA , FirpoV , CasimirL , et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer2001;91(8):1563‐7. ">Paganini 2001</a>; <a href="./references#CD009031-bbs2-0017" title="PaganiniH , GómezS , RuvinskyS , ZubizarretaP , LatellaA , FraquelliL , et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer2003;97(7):1775‐80. ">Paganini 2003</a>; <a href="./references#CD009031-bbs2-0018" title="PetrilliAS , DantasLS , CamposMC , TanakaC , GinaniVC , SeberA . Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology2000;34(2):87‐91. ">Petrilli 2000</a>; <a href="./references#CD009031-bbs2-0019" title="RubensteinEB , RolstonK , BenjaminRS , LoewyJ , EscalanteC , ManzulloE , et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer1993;71(11):3640‐6. ">Rubenstein 1993</a>); </p> </li> <li> <p>Studies which randomised two oral antibiotics in outpatients: one trial (<a href="./references#CD009031-bbs2-0012" title="KernWV , MarchettiO , DrgonaL , AkanH , AounM , AkovaM , et al. Oral antibiotics for fever in low‐risk neutropenic patients with cancer: a double‐blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy ‐ EORTC infectious diseases group trial XV. Journal of Clinical Oncology2013;31(9):1149‐56. ">Kern 2013</a>); </p> </li> <li> <p>Studies which randomised oral antibiotic treatment and placebo in outpatients: one trial (<a href="./references#CD009031-bbs2-0013" title='KlaassenRJ , GoodmanR , PhamBA , DoyleJJ . "Low‐risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology2000;18(5):1012‐9. '>Klaassen 2000</a>). </p> </li> </ul> </p> </section> </section> <section id="CD009031-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD009031-fig-0002">Figure 2</a> and <a href="#CD009031-fig-0003">Figure 3</a> for visual representations of the assessment of risk of bias across all studies and for each item in the included studies. See the section <a href="#CD009031-sec-0069">Risk of bias in included studies</a> for further information about the bias identified within the individual studies. </p> <div class="figure" id="CD009031-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009031-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009031-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009031-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009031-sec-0070"> <h4 class="title">Allocation</h4> <p>The randomisation process was adequately performed in only three studies (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>); in the other seven trials, it was not possible to determine how the randomisation was done. Allocation concealment was adequate in five studies (classified as having low risk of bias) (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>). In the remaining five studies, the method of allocation concealment was not reported, so they were classified as having unclear risk of bias (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>) (<a href="#CD009031-fig-0002">Figure 2</a>). </p> </section> <section id="CD009031-sec-0071"> <h4 class="title">Blinding</h4> <p>It was clearly reported that two studies were unblinded (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>). The other eight trials were classified as having an uncertain risk of bias because the authors did not accurately describe the blinding process. However, blinding was unlikely since it was obvious that empirical antimicrobial therapy was being received in or out of hospital. Therefore, in all 10 trials, detection bias could have been present. </p> </section> <section id="CD009031-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>According to data reported in the 10 trials, all participants included in the studies had complete follow‐up. </p> </section> <section id="CD009031-sec-0073"> <h4 class="title">Selective reporting</h4> <p>In each of the 10 trials, the outcomes described in the methods section were reported appropriately. </p> </section> <section id="CD009031-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>For this review, the presence of any other bias that might influence the results was not apparent. </p> </section> </section> <section id="CD009031-sec-0075"> <h3 class="title" id="CD009031-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD009031-tbl-0001"><b>Summary of findings for the main comparison</b> Outpatients compared to inpatients ‐ adults for people with cancer who develop a low‐risk febrile neutropaenic event</a>; <a href="./full#CD009031-tbl-0002"><b>Summary of findings 2</b> Outpatients compared to inpatients ‐ children for people with cancer who develop a low‐risk febrile neutropaenic event</a> </p> <section id="CD009031-sec-0076"> <h4 class="title">Primary outcomes</h4> <section id="CD009031-sec-0077"> <h5 class="title">Treatment failure</h5> <p>Ten RCTs, six studies in adults (628 participants) (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>) and four in children (366 participants) (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>) reported treatment efficacy. The outpatient management of low‐risk febrile neutropaenia showed no clear difference when compared to the inpatient group, either in adult participants (RR 1.23, 95% CI 0.82 to 1.85; P = 0.33, I<sup>2</sup> 0.0%; moderate‐certainty evidence) (<a href="./references#CD009031-fig-0006" title="">Analysis 1.1</a>, <a href="#CD009031-fig-0004">Figure 4</a>) or in children (RR 1.04, 95% CI 0.55 to 1.99; P = 0.53; I<sup>2</sup> 0%; moderate‐certainty evidence) (<a href="./references#CD009031-fig-0012" title="">Analysis 2.1</a>). </p> <div class="figure" id="CD009031-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.1 Treatment failure." data-id="CD009031-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.1 Treatment failure. </p> </div> </div> </div> </section> <section id="CD009031-sec-0078"> <h5 class="title">Mortality</h5> <p>All but one trial (<a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>) reported mortality. We also found no clear difference between outpatient and inpatient groups, both for adults (RR 1.04, 95% CI 0.29 to 3.71; P = 0.95, I<sup>2</sup> 0.0%; six studies, 628 participants; moderate‐certainty evidence) (<a href="./references#CD009031-fig-0007" title="">Analysis 1.2</a>, <a href="#CD009031-fig-0005">Figure 5</a>) or children (RR 0.63, 95% CI 0.15 to 2.70; P = 0.53; I<sup>2</sup> 0.0%; three studies, 329 participants; moderate‐certainty evidence) (<a href="./references#CD009031-fig-0013" title="">Analysis 2.2</a>). </p> <div class="figure" id="CD009031-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.2 Mortality." data-id="CD009031-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.2 Mortality. </p> </div> </div> </div> </section> </section> <section id="CD009031-sec-0079"> <h4 class="title">Secondary outcomes</h4> <section id="CD009031-sec-0080"> <h5 class="title">Duration of fever</h5> <p>Eight studies analysed duration of fever; four in adult participants (<a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>) and four in children (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>). Meta‐analysis could only be done with one study in adult participants (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>) comparing an outpatient group against an inpatient group, and no differences were found (MD 0.20 days, 95% CI ‐0.36 to 0.76; P = 0.48; 169 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0008" title="">Analysis 1.3</a>). Similar findings (P &gt; 0.05) were found in the other three studies; one reported that, in both groups, the median time for fever to resolve was two days (<a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>), while in another (<a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>), the median for the two groups was three days with a range of one to seven days for the inpatient group and one to six days for the outpatient group. Talcott and colleagues (<a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>) reported that the average was 3.4 days (range 1 to 14) and 3.2 days (range 0 to 13), respectively. </p> <p>In the four studies of children, there was also no evidence of a difference, nor in a meta‐analysis including three of these studies (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>) (MD ‐0.06 days, 95% CI ‐0.84 to 0.71; P = 0.08, I<sup>2</sup> 61%; 305 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0014" title="">Analysis 2.3</a>), or in the study by Brack and colleagues (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>), which reported that the median for the inpatient group was 1.5 days (range 0 to 10) and 1.0 day (range 0 to 11) for the outpatient group (P = 0.19). </p> </section> <section id="CD009031-sec-0081"> <h5 class="title">Adverse drug reactions related to the antibiotic regimen</h5> <p>We extracted data on adverse effects related to the antibiotic regimen from five RCTs; three of adult participants (<a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>) and two of children (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>). Among adult participants, in one RCT (<a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>), no adverse events were reported in any of the two groups; In the other two studies, there were more adverse events in the outpatient group; however, there was no evidence of a difference between outpatient and inpatient groups (RR 8.39, 95% CI 0.38 to 187.15; P = 0.18; I<sup>2</sup> 66% ; three studies, 375 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0009" title="">Analysis 1.4</a>). Also, in the two RCTs of children there were more adverse events in the outpatient group, but no difference statistically (RR 1.90, 95% CI 0.61 to 5.98; P = 0.27; 156 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0015" title="">Analysis 2.4</a>). These adverse events were mainly related to digestive intolerance to oral antimicrobial treatment (diarrhoea, nausea, vomiting); only one study reported that the use of imipenem caused nausea and vomiting in the inpatient group (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>). </p> <p>It should be noted that failure of empirical antimicrobial treatment in the outpatient group, in some cases, was due to adverse events. One RCT (<a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>) reported that three of the 10 failures were caused by vomiting (one participant) or severe oesophagitis (two participants). </p> </section> <section id="CD009031-sec-0082"> <h5 class="title">Duration of neutropaenia</h5> <p>Three RCTs of adults reported duration of neutropaenia (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>); there was no evidence of a difference between the outpatient group and inpatient group in the Malik study (<a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>) (MD 0.10, 95% CI ‐0.59 to 0.79; P = 0.78; 169 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0010" title="">Analysis 1.5</a>). Rapoport and colleagues reported that the median for neutrophil recovery for two groups was three days, with no evidence of a difference between the groups (<a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>). Similar findings were reported in the study by Talcott (<a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>); 4.1 days (range 1 to 10) was the mean time for neutropaenia recovery in the outpatient group, and 4.2 days (range 1 to 15) in the outpatient group (P = 0.80). </p> <p>In two studies of children, the days with neutropaenia were reported (<a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>; <a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>); there was also no evidence of a difference between groups (MD ‐0.65, 95% CI ‐1.86 to 0.55; P = 0.29, I<sup>2</sup> 0%; 268 participants; moderate‐certainty evidence) (<a href="./references#CD009031-fig-0016" title="">Analysis 2.5</a>). </p> </section> <section id="CD009031-sec-0083"> <h5 class="title">Duration of hospitalisation</h5> <p>Meta‐analysis of hospitalisation time was performed in three RCTs of adults (<a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>), in which shorter hospital stay was obtained in the outpatient group compared to the inpatient group. (MD ‐1.64, 95% CI ‐2.22 to ‐1.06; P &lt; 0.0001, I<sup>2</sup> 0%; 251 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0011" title="">Analysis 1.6</a>). </p> <p>In two studies of children, fewer days of hospitalisation were also reported, both in the study of <a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a> (MD ‐3.9, 95% CI ‐5.37 to ‐2.43; P &lt; 0.00001; 119 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0017" title="">Analysis 2.6</a>), and in that of <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a> which reported a mean of 1.0 day (range 1 to 2) in the outpatient group, and a mean of 5.3 days (range 3 to 9) in the inpatient group (P &lt; 0.001). </p> </section> <section id="CD009031-sec-0084"> <h5 class="title">Duration of antimicrobial treatment</h5> <p>Only one RCT of adult participants included this outcome (<a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>); the authors reported that the median for the inpatient group was 6.3 days and 6.0 days for the outpatient group. </p> <p>Four studies of children compared treatment time of antimicrobial use between the two groups, but only three were included in the meta‐analysis (<a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a>; <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>). We found no evidence of a difference in the number of days of antimicrobial treatment between outpatient and inpatient groups: MD ‐0.07, 95% CI ‐1.26 to 1.12; P = 0.10, I<sup>2</sup> 57%; 305 participants; low‐certainty evidence) (<a href="./references#CD009031-fig-0018" title="">Analysis 2.7</a>). Brack and colleagues also found no evidence of a difference (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>), the median for the outpatient group was five days (range 3 to 18) and for the inpatient group was five days (range 2 to 19) (P = 0.34). </p> </section> <section id="CD009031-sec-0085"> <h5 class="title">Quality of life (QoL)</h5> <p>Only two studies explored QoL in participants with low‐risk febrile episodes. In the first study (<a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>), the trial authors reported that pain decreased for home care of adult participants and slightly increased for hospitalised participants (change, ‐13.1 versus. 2.72; P = 0.01). They also indicated that the role function subscale of the EORTIC QLQ C‐30 increased in both groups, but less for home‐care participants than for hospitalised participants (change, 0.58 versus 0.78; P = 0.05); however, emotional function scores increased for home‐care participants and declined for hospitalised participants (change, 3.27 versus ‐6.94; P = 0.04). They did not find evidence of differences relating to the consumer satisfaction or general well‐being instruments. </p> <p>Most recently, <a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a> compared QoL every day during the low‐risk episode in child participants. They used a modified version of a QoL instrument used previously in children receiving home chemotherapy (<a href="./references#CD009031-bbs2-0028" title="CloseP , BurkeyF , KasakA , DanzP , LangeB . A prospective, controlled evaluation of home chemotherapy for children with cancer. Pediatrics1995;95(6):896‐900. ">Close 1995</a>); this is a visual analogue scale which assesses seven patient variables and six parent variables. The authors reported that baseline questionnaires were similar between the outpatient and inpatient groups. In the outpatient group, parents showed higher level of QoL on days 2, 3 and 4; however, they showed higher levels of concern about their child's condition and a lower level of confidence in their ability to care for the child. Meanwhile, the responses of QoL from children trended higher in the outpatient group, particularly for sleep and appetite. </p> </section> <section id="CD009031-sec-0086"> <h5 class="title">Analysis according to type of intervention</h5> <p>In order to determine if there was a difference in the results according to the type of intervention (early discharge or exclusively outpatient), we performed analyses only for the main outcome variable, treatment failure. Meta‐analysis of the 4 RCTs in adults (<a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a>; <a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a>; <a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a>; <a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>) with early discharge (RR 1.48, 95% CI 0.74 to 2.95; P = 0.26, I<sup>2</sup> 0%; 364 participants moderate‐certainty evidence) (<a href="./references#CD009031-fig-0019" title="">Analysis 3.1</a>) was similar to the results of the exclusively outpatient (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>) meta‐analysis (RR 1.15, 95% CI 0.62 to 2.13; P = 0.65, I<sup>2</sup> 19%; two studies; 264 participants; moderate‐certainty evidence) (<a href="./references#CD009031-fig-0020" title="">Analysis 4.1</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009031-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009031-sec-0087">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009031-sec-0151">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009031-sec-0087"></div> <section id="CD009031-sec-0088"> <h3 class="title" id="CD009031-sec-0088">Summary of main results</h3> <p>This systematic review synthesised the evidence from 10 RCTs comparing inpatient empirical antimicrobial therapy versus outpatient management for patients with low‐risk febrile neutropaenia. The results showed no evidence of differences between outpatient and inpatient treatment of low‐risk febrile neutropaenia in terms of treatment failure and mortality, in either adults or children. Of note, given the risk of bias detected, and the wide 95% CIs for main outcome measures, particularly for RCTs in children, we have only moderate‐certainty about the results. </p> <p>It is also important to consider that there were only two RCTs comparing outpatient versus inpatient treatments, so most of the data were from RCTs exploring an early discharge strategy. In addition, more than 60% of the participants were patients with diagnoses of solid tumours. </p> <p>When considering other outcome measures, the different meta‐analyses showed that resolution of fever, duration of neutropaenia, and adverse drug reactions were similar between the outpatient and the inpatient groups; however, for these outcome measures there was low‐certainty of evidence, so the difference between the two interventions may be substantially different from the estimated effect. It should be noted that, in six RCTs, there was consistency in the reduction of the length of hospitalisation in the outpatient strategy, both in trials of adults and children. As for quality of life, more evidence is needed to determine if there is any advantage between the two interventions. </p> <p>In conclusion, this meta‐analysis shows that there is low to moderately‐certain evidence to support the conclusion that outpatient treatment is as effective as inpatient treatment for people with low‐risk febrile neutropaenia, in either an adult or paediatric population. It should also be considered that the number of RCT published so far is limited. </p> </section> <section id="CD009031-sec-0089"> <h3 class="title" id="CD009031-sec-0089">Overall completeness and applicability of evidence</h3> <p>Outpatient therapy for the administration of empiric antimicrobial therapy may be a safe alternative to inpatient therapy for low‐risk cancer patients with an episode of febrile neutropaenia. </p> <p>It is important to consider that the main intervention in this meta‐analysis was not standardised. Almost all studies used the early discharge approach for participants with low‐risk febrile neutropaenia episodes. In only two studies, participants assigned to outpatient treatment were discharged immediately after the administration of the first antibiotic dose (<a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a>; <a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a>). All other studies used the early discharge strategy, where participants were inpatients and observed for 24 to 72 hours and, during this time, the first doses of empirical (usually intravenous) broad spectrum antimicrobial therapy were administered. Any participants who then fulfilled low‐risk criteria after clinical reassessment received outpatient treatment. The results of this systematic review and meta‐analysis are more directed towards the early discharge approach than immediate outpatient treatment. </p> <p>The definition of low risk must be taken into account. Unlike adult patients, there is no accepted definition for 'low risk' in children with cancer. In the included RCTs, there were several variations in the criteria used to consider 'low risk' for serious infection, such as fever, type of chemotherapy, type of tumour, hypotension, relapse, count of platelets. This difference in the criteria used has been documented in studies that evaluated the risk stratification in children (<a href="./references#CD009031-bbs2-0031" title="DelebarreM , MacherE , MazingueF , MartinotA , DubosF . Which decision rules meet methodological standards in children with febrile neutropenia? Results of a systematic review and analysis.. Pediatric Blood &amp; Cancer2014;61(10):1786‐91. ">Delebarre 2014</a>). In adults, MASCC risk index for febrile neutropaenia has been incorporated in clinical guidelines since 2010; in this systematic review, only one study (<a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a>) used a MASCC risk index to select the participants. </p> </section> <section id="CD009031-sec-0090"> <h3 class="title" id="CD009031-sec-0090">Quality of the evidence</h3> <p>In general, the quality of the RCTs was of low‐ to moderate‐certainty according to the GRADE approach (<a href="./full#CD009031-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009031-tbl-0002">summary of findings Table 2</a>). The major problems in the 'risk of bias' assessment of the studies was related to randomisation, blinding, and the allocation processes. In only three studies did the authors appropriately report how randomisation was performed. In the six other studies, randomisation was classified as uncertain as it was not clearly specified how the randomisation sequence was done. In five studies, allocation concealment was carried out correctly. </p> <p>Blinding was either not performed or unclear in all studies. The intervention consisted of providing the empirical antimicrobial therapy in the participants' homes or when hospitalised. As either intervention was obvious, then there may have been detection bias for certain outcomes such as the disappearance of fever and adverse effects, but nor for mortality. </p> <p>Despite the fact that we observed no evidence of differences between adults and children for the early discharge approach and exclusive outpatients versus exclusive inpatients in the sensitivity analyses, the wide CIs obtained from most of the main outcome measures, should to be taken into account in the interpretation of the results. </p> </section> <section id="CD009031-sec-0091"> <h3 class="title" id="CD009031-sec-0091">Potential biases in the review process</h3> <p>This systematic review was carried out in accordance with the guidelines of Cochrane with assistance from the Information Specialist from the Cochrane Gynaecological, Neuro‐oncology &amp; Orphan Cancers Group. We made every attempt to include published and unpublished studies. However, there remains the possibility that there may be other unpublished trials that we did not identify. This means that we may have unwittingly perpetuated a publication bias. </p> <p>A meta‐analysis could not be performed for all the RCTs, as the outcomes (duration of antimicrobial treatment, duration of hospitalisation, duration of neutropaenia, and duration of fever in days), were reported as medians, and we did not contact the authors asking for the raw data. </p> <p>Funnel plots could not be undertaken because the number of studies in adults and children was less than ten, therefore, publication bias could not be measured. </p> </section> <section id="CD009031-sec-0092"> <h3 class="title" id="CD009031-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>Systematic reviews have been published in the past on the use of empirical outpatient therapy. In 2011, Teuffel and colleagues (<a href="./references#CD009031-bbs2-0069" title="TeuffelO , EthierMC , AlibhaiSM , BeyeneJ , SungL . Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta‐analysis. Annals of Oncology2011;22(11):2358‐65. ">Teuffel 2011</a>) carried out a meta‐analysis with 14 RCTs to determine the effectiveness of outpatient management of cancer patients with febrile neutropaenia. Of the 14 RCTs, six compared inpatient versus outpatient management, including 738 participants; results were: RR 0.81 (95% CI 0.32 to 2.71) for treatment failure, and RR 1.11 (95% CI 0.41 to 3.05) for mortality. In the present review, we included the same six studies plus four more that were published more recently, and found similar results. The other eight studies in the review by Teuffel and colleagues compared only the route of drug administration in the outpatient setting. </p> <p>Unlike Teuffel and colleagues, in this review we evaluated other outcome measures such as fever, hospitalisation, adverse effects, and quality of life, but not the route of antibiotic administration. Another meta‐analysis found that the rates of treatment failure and mortality in adults and children receiving oral or intravenous antibiotic treatments were comparable, provided that the participants were haemodynamically stable, had no organ failure, could take oral medications, did not have pneumonia, central line infection or a severe soft‐tissue infection, and did not suffer from acute leukaemia (<a href="./references#CD009031-bbs2-0070" title="VidalL , PaulM , Ben‐DorI , PokroyE , Soares‐WeiserK , LeiboviciL . Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD003992.pub3] ">Vidal 2013</a>). More recently, Loeffen and colleagues (<a href="./references#CD009031-bbs2-0053" title="LoeffenEA , TePoeleEM , TissingWJ , BoezenHM , DeBontES . Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropenia. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD008382.pub2] ">Loeffen 2016</a>) analysed very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropaenia. They found only two RCTs that met the selection criteria, and reported that meta‐analysis was not possible because the timing defined for participants’ discharge was different, as were the risk stratification models used. In this review, we included both studies (<a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a>; <a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a>) and integrated them into the meta‐analyses because the criteria we used were not so restricted. </p> <p>Recently, in the updated recommendations for adult outpatient management (<a href="./references#CD009031-bbs2-0043" title="TaplitzRA , KennedyEB , BowEJ , CrewsJ , GleasonC , HawleyDK , et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline update. Journal of Clinical Oncology2018;36(14):1443‐53. ">IDSA 2018</a>), it was recommended that patients with low‐risk febrile neutropaenia should receive initial doses of antimicrobials within one hour of triage and be monitored for four hours or more before discharge. Our review supports this recommendation for outpatient treatment, but only two of six studies evaluated this approach. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009031-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009031-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009031-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009031-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.1 Treatment failure." data-id="CD009031-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.1 Treatment failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.2 Mortality." data-id="CD009031-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.2 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 1 Treatment failure." data-id="CD009031-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 1 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 2 Mortality." data-id="CD009031-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 3 Duration of fever (days)." data-id="CD009031-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 3 Duration of fever (days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 4 Adverse drug reactions." data-id="CD009031-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 4 Adverse drug reactions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 5 Duration of neutropaenia (days)." data-id="CD009031-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 5 Duration of neutropaenia (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 6 Duration of hospitalisation (days)." data-id="CD009031-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Outpatients versus inpatients ‐ adults, Outcome 6 Duration of hospitalisation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 1 Treatment failure." data-id="CD009031-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 1 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 2 Mortality." data-id="CD009031-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 3 Duration of fever (days)." data-id="CD009031-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 3 Duration of fever (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 4 Adverse drug reactions." data-id="CD009031-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 4 Adverse drug reactions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 5 Duration of neutropaenia (days)." data-id="CD009031-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 5 Duration of neutropaenia (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 6 Duration of hospitalisation (days)." data-id="CD009031-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 6 Duration of hospitalisation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Outpatients versus inpatients ‐ children, Outcome 7 Duration of antimicrobial treatment (days)." data-id="CD009031-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Outpatients versus inpatients ‐ children, Outcome 7 Duration of antimicrobial treatment (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Early discharge ‐ adults, Outcome 1 Treatment failure." data-id="CD009031-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Early discharge ‐ adults, Outcome 1 Treatment failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009031-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/urn:x-wiley:14651858:media:CD009031:CD009031-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_t/tCD009031-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Exclusively outpatient vs Exclusively inpatient, Outcome 1 Treatment failure." data-id="CD009031-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Exclusively outpatient vs Exclusively inpatient, Outcome 1 Treatment failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/media/CDSR/CD009031/image_n/nCD009031-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009031-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Outpatients compared to inpatients ‐ adults for people with cancer who develop a low‐risk febrile neutropaenic event</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Outpatients compared to inpatients ‐ adults for people with cancer who develop a low‐risk febrile neutropaenic event</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Adult patients with cancer who develop a low‐risk febrile neutropaenic event<br/> <b>Setting:</b> Oncology of tertiary care hospitals<br/> <b>Intervention:</b> Outpatient empirical antimicrobial therapy<br/> <b>Comparison:</b> Inpatient empirical antimicrobial therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inpatients ‐ adults</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with outpatients ‐ adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.82 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>628<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000<br/> (92 to 207) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.29 to 3.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>628<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (4 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of fever (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever was 3.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever was</p> <p>on average 0.2 higher<br/> (95% CI 0.36 lower to 0.76 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse drugs reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 8.39<br/> (0.38 to 187.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>375<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (2 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of neutropaenia (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia was 4.7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia was on average 0.1 higher<br/> (95% CI 0.59 lower to 0.79 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalisation (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation ranged from 4.4 to 8.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation was on average ‐1.64 lower<br/> (95% CI ‐2.22 lower to ‐1.06 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Four studies had appropriate allocation processes; in only one study the randomisation process was well stated; none were blinded.<br/> <sup>2</sup> The allocation process was appropriate, but randomisation and blinding were unclear.<br/> <sup>3</sup> CIs were wide.<br/> <sup>4</sup> In two studies, the allocation process was appropriate; in one study, the randomisation process was well stated. Blinding was unclear in three studies.<br/> <sup>5</sup> The allocation process was appropriate in only one study. Randomisation and blinding in the three studies were unclear. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Outpatients compared to inpatients ‐ adults for people with cancer who develop a low‐risk febrile neutropaenic event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009031-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Outpatients compared to inpatients ‐ children for people with cancer who develop a low‐risk febrile neutropaenic event</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Outpatients compared to inpatients ‐ children for people with cancer who develop a low‐risk febrile neutropaenic event</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Children with cancer who develop a low‐risk febrile neutropaenic event<br/> <b>Setting:</b> Oncology or tertiary care hospitals<br/> <b>Intervention:</b> Outpatient empirical antimicrobial therapy<br/> <b>Comparison:</b> Inpatient empirical antimicrobial therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inpatients ‐ children</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with outpatients ‐ children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.55 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>366<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/> (52 to 187) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/> (0.15 to 2.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>329<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (4 to 66) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of fever (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever ranged from 2.4 to 3.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of fever was on average ‐0.06 lower<br/> (95% CI ‐0.84 lower to 0.71 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse drug reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.90<br/> (0.61 to 5.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/> (32 to 315) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of neutropaenia (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia ranged from 3.9 to 12.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of neutropaenia was on average ‐0.65 lower<br/> (95% CI ‐1.86 lower to 0.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalisation (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation was 10.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of hospitalisation was on average ‐3.9 lower<br/> (95% CI ‐5.37 lower to ‐2.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antimicrobial treatment (days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of antimicrobial treatment ranged from 4.8 to 10.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean days of antimicrobial treatment was on average ‐0.07 lower (95%CI ‐1.26 lower to 1.12 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The randomisation process was well stated in two studies; allocation was appropriate in one study; blinding was not done in two studies and was unclear in two studies.<br/> <sup>2</sup> Randomisation was unclear in three studies; the allocation process was well stated in one study; blinding was unclear in two studies and in one was not done.<br/> <sup>3</sup> The randomisation process was well stated in one study; allocation was unclear in three studies; blinding was not done in two studies and in one study was unclear.<br/> <sup>4</sup> CIs were wide.<br/> <sup>5</sup> The randomisation process was well stated in one study; allocation was unclear in two studies; blinding was not done in two studies.<br/> <sup>6</sup> The randomisation and allocation processes were unclear in two studies; blinding was not done in one study and was unclear in one study.<br/> <sup>7</sup> Randomisation and allocation were unclear; blinding was not done.<br/> <sup>8</sup> Statistical tests suggested substantial heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Outpatients compared to inpatients ‐ children for people with cancer who develop a low‐risk febrile neutropaenic event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009031-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria used to consider low‐risk febrile episodes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk definition used</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0006" title="MalikIA , KhanWA , KarimM , AzizA . Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine1995;98(3):224‐31. ">Malik 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants that did not have any of the following: history of recurrent pyrexia or undetermined origin; shock (systolic blood pressure &lt; 80 mmHg or peripheral circulatory failure); any comorbid condition requiring hospitalisation (except anaemia or thrombocytopaenia); and expectation of prolonged neutropaenia (&gt; 7 days) based on aplastic anaemia, myelodysplasia, leukaemia or other causes, except if leukaemia patients were receiving consolidation of maintenance therapy or growth stimulation factors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0008" title="RapoportBL , SussmannO , HerreraMV , SchlaefferF , OteroJC , PavlovskyS , et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy1999;45(6):466‐76. ">Rapoport 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients that did not have renal failure requiring dialysis, suspected meningitis, known HIV infection, septic shock, or likelihood to expire within 48 h of study entry. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0003" title="HidalgoM , HornedoJ , LumbrerasC , TrigoJM , ColomerR , PereaS , et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer1999;85(1):213‐9. ">Hidalgo 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and did not have any of the following: progression of their malignant disease; signs or symptoms of a potentially severe infection (hypotension, oliguria, altered mental status, tachypnoea, respiratory failure, clotting abnormality, or acidosis); a serious focal infection (pneumonia, extensive cellulitis, meningitis, or pyelonephritis); hypercalcaemia; uncontrolled bleeding; cardiac, renal or liver failure; or another comorbid condition that required admission to the hospital. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0004" title="InnesHE , SmithDB , O'ReillySM , ClarkPI , KellyV , MarshallE . Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer2003;89(1):43‐9. ">Innes 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were required to be haemodynamically stable with no signs or symptoms that required intravenous fluid support, and adequate renal function. </p> <p>Participants must not have a coexisting medical condition that would require targeted or prolonged duration of antibiotic therapy (e.g. cellulitis, abscess, pneumonia, CVC tunnel infection). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0005" title="López‐HernándezMA , Herrera‐ÁlvarezW , Sibaja‐NietoL , Álvarez‐VeraJL . Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México2010;26(3):219‐25. ">López‐Hernández 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with acute leukaemia in complete remission, absence of an identifiable focus of infection (except for acute respiratory infections); absence of comorbidity conditions or organ failure (except for bone marrow); expected recovery of neutropaenia (&gt; 0.10 x 10<sup>9</sup>/L) in the next 8 days. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0010" title="HendricksAM , LoggersET , TalcottJA . Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology2011;29(30):3984‐9. TalcottJA , YeapBY , ClarkJA , SiegelRD , LoggersET , LuC , et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology2011;29(30):3977‐83. ">Talcott 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were evaluated for risk assessment criteria by the author. Participants did not have an indication for hospitalisation (other than fever); systemic hypotension; altered mental status; respiratory failure or inadequate oral fluid intake during 24 h observation; AIDS‐associated malignancy; neutropaenia arising from more than 21 days of chemotherapy and intensive chemotherapy requiring bone marrow or peripheral stem‐cell support. </p> <p>For leukaemia, participants must have bone marrow‐proven complete remission, and without leukaemia, no evidence of disease progression after the initial chemotherapy regimen or at least two cycles of a subsequent regimen. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0009" title="SantolayaME , ÁlvarezAM , AvilésCL , BeckerA , CofréJ , CumsilleMA , et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology2004;22(18):3784‐9. ">Santolaya 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were evaluated with a previously validated risk prediction model. Participants with less than 90 mg/L serum‐C reactive protein (CRP), absence of hypotension, absence of relapse or leukaemia as cancer type, platelet count of &gt; 50,000/μL and &gt; 7 days of receiving chemotherapy were classified as low risk. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0001" title="AhmedN , El‐MahallawyHA , AhmedIA , NassifS , El‐BeshlawyA , El‐HaddadA . Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood &amp; Cancer2007;49(6):786‐92. ">Ahmed 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The following criteria must be fulfilled at 72 h: afebrile for a minimum of 24 h prior to the assessment point; negative initial blood cultures or two negative repeat blood cultures (24 h apart) if initially positive; absence (or substantial resolution) of manifestations of localised infection; Lansky performance scale 80 to 100, Karnosfy scale 80 to 100 if &gt; 16 years; neutrophil absolute count &gt; 100 μL; patient not in or after first induction therapy for acute myeloblastic leukaemia; discharge destination 1 h travel time from the medical centre. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0002" title="BrackE , BodnerN , SimonA , LiebundgutK , KühneT , NiggliFK , et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood &amp; Cancer2012;59(3):423‐30. ">Brack 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants had to fulfil 10 predefined low‐risk criteria: diagnosis not AML/mature B‐ALL/NHL; bone marrow involvement &lt; 25%; no comorbidity requiring hospitalisation: no arterial hypotension, no hypo‐oxygenation [SpO<sub>2</sub> &lt; 94% at ambient air], no radiologically defined pneumonia, no focal infection, initial blood cultures negative and fever always &lt; 39.5°C. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009031-bbs2-0007" title="OrmeLM , BablFE , BarnesC , BarnettP , DonathS , AshleyDM . Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood &amp; Cancer2014;61(8):1427‐33. ">Orme 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients were considered low risk if they had: no signs of septic shock (including hypotension, tachycardia, delayed capillary refill or rigor); no significant comorbidities requiring inpatient monitoring or treatment including clinical focus of infection, pain, mucositis, vomiting, diarrhoea, or dehydration; no acute myeloid leukaemia diagnosis (AML), mature B‐cell lymphoma diagnosis, or were not in the induction phase of acute lymphoblastic leukaemia, or were not receiving predominantly high dose stem cell‐supported chemotherapy. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>AIDS: acquired immune deficiency syndrome<br/> AML: acute myeloid leukaemia<br/> B‐ALL: Cell B‐ acute lymphoblastic leukaemia<br/> CRP: serum‐C reactive protein<br/> CVC: central venous catheter<br/> ECOG: Eastern Cooperative Oncology Group<br/> NHL: non‐Hodgkin lymphoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria used to consider low‐risk febrile episodes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/full#CD009031-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009031-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Outpatients versus inpatients ‐ adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.82, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.29, 3.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of fever (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse drug reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.39 [0.38, 187.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Duration of neutropaenia (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.64 [‐2.22, ‐1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Outpatients versus inpatients ‐ adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009031-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Outpatients versus inpatients ‐ children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.55, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.15, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of fever (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.84, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse drug reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.61, 5.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Duration of neutropaenia (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.86, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Duration of antimicrobial treatment (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐1.26, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Outpatients versus inpatients ‐ children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009031-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Early discharge ‐ adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.74, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Early discharge ‐ adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009031-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Exclusively outpatient vs Exclusively inpatient</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.62, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Exclusively outpatient vs Exclusively inpatient</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009031.pub2/references#CD009031-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009031.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009031-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009031-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD009031-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD009031-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009031-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009031-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009031-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009031\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009031\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009031\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009031\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009031\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009031.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009031.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009031.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009031.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009031.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728478436"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009031.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728478439"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009031.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec5773a0a9367',t:'MTc0MDcyODQ3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 